Seattle Genetics licenses technology to GSK

12/21/2009 | Reuters

Seattle Genetics granted GlaxoSmithKline rights to use its antibody-drug conjugate technology. GSK will pay Seattle Genetics $12 million upfront and as much as $390 million in milestone fees if all ADC products created as a result of the deal reach the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC